Lefluartil (Leflunomide)

Leflunomide is metabolised to teriflunomide, an inhibitor of dihydroorotate dehydrogenase. This enzyme is essential for de novo pyrimidine synthesis, so its blockade limits the proliferation of activated T‑cells and other immune cells, thereby dampening inflammation in the joints.

The dosing regimen for Lefluartil is determined by the prescribing clinician based on the individual’s disease severity, response to therapy, and laboratory monitoring. Physicians typically start with a loading dose followed by a maintenance dose, but exact amounts are not disclosed here.

Leflunomide is classified as contraindicated in pregnancy because of known teratogenic risk. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Limited data exist for breastfeeding, and the drug is generally avoided while nursing.

To place an order, submit an enquiry on the Lefluartil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to leflunomide is methotrexate, another conventional DMARD. Both aim to control disease activity, but leflunomide is taken orally once daily and may be preferred when weekly methotrexate dosing is problematic. Their safety profiles differ, with leflunomide more associated with liver enzyme elevations and methotrexate with mucosal ulcers.

Lefluartil should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity.

Lefluartil is administered orally, typically as a tablet taken with water. Patients should follow the prescriber’s instructions regarding timing, food intake, and any required loading dose. Swallow the tablet whole; do not crush or chew unless directed by a healthcare professional.

The most serious risks include severe liver injury, bone‑marrow suppression leading to anemia or low white‑blood‑cell counts, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Regular laboratory monitoring of liver enzymes and blood counts is essential to detect these complications early.

Lefluartil is contraindicated in patients with known hypersensitivity to leflunomide or its metabolites, those with severe hepatic impairment, and pregnant women. Caution is also advised for individuals with existing bone‑marrow disorders, uncontrolled hypertension, or active infections.